Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia.
Barrett’s Esophagus
Cancer Risk Stratification
Surveillance
TP53
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
09
11
2020
revised:
21
10
2021
accepted:
24
10
2021
pubmed:
11
11
2021
medline:
23
2
2022
entrez:
10
11
2021
Statut:
ppublish
Résumé
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma. A major challenge is identifying the small group with BE who will progress to advanced disease from the many who will not. Assessment of p53 status has promise as a predictive biomarker, but analytic limitations and lack of validation have precluded its use. The aim of this study was to develop a robust criteria for grading abnormal immunohistochemical (IHC) expression of p53 and to test its utility as a biomarker for progression in BE. Criteria for abnormal IHC of p53 were developed in BE biopsies and validated with sequencing to assess TP53 mutations. The utility of p53 IHC as a biomarker for progression of BE was tested retrospectively in 561 patients with BE with or without known progression. The findings were prospectively validated in a clinical practice setting in 1487 patients with BE. Abnormal p53 IHC highly correlated with TP53 mutation status (90.6% agreement) and was strongly associated with neoplastic progression in the retrospective cohorts, regardless of histologic diagnosis (P < .001). In the retrospective cohort, abnormal p53 was associated with a hazard ratio of 5.03 (95% confidence interval, 3.88-6.5) and a hazard ratio of 5.27 (95% confidence interval, 3.93-7.07) for patients with exclusively nondysplastic disease before progression. In the prospective validation cohort, p53 IHC predicted progression among nondysplastic BE, indefinite for dysplasia, and low-grade dysplasia (P < .001). p53 IHC identifies patients with BE at higher risk of progression, including in patients without evidence of dysplasia. p53 IHC is inexpensive, easily integrated into routine practice, and should be considered in biopsies from all BE patients without high-grade dysplasia or cancer.
Sections du résumé
BACKGROUND AND AIMS
Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma. A major challenge is identifying the small group with BE who will progress to advanced disease from the many who will not. Assessment of p53 status has promise as a predictive biomarker, but analytic limitations and lack of validation have precluded its use. The aim of this study was to develop a robust criteria for grading abnormal immunohistochemical (IHC) expression of p53 and to test its utility as a biomarker for progression in BE.
METHODS
Criteria for abnormal IHC of p53 were developed in BE biopsies and validated with sequencing to assess TP53 mutations. The utility of p53 IHC as a biomarker for progression of BE was tested retrospectively in 561 patients with BE with or without known progression. The findings were prospectively validated in a clinical practice setting in 1487 patients with BE.
RESULTS
Abnormal p53 IHC highly correlated with TP53 mutation status (90.6% agreement) and was strongly associated with neoplastic progression in the retrospective cohorts, regardless of histologic diagnosis (P < .001). In the retrospective cohort, abnormal p53 was associated with a hazard ratio of 5.03 (95% confidence interval, 3.88-6.5) and a hazard ratio of 5.27 (95% confidence interval, 3.93-7.07) for patients with exclusively nondysplastic disease before progression. In the prospective validation cohort, p53 IHC predicted progression among nondysplastic BE, indefinite for dysplasia, and low-grade dysplasia (P < .001).
CONCLUSIONS
p53 IHC identifies patients with BE at higher risk of progression, including in patients without evidence of dysplasia. p53 IHC is inexpensive, easily integrated into routine practice, and should be considered in biopsies from all BE patients without high-grade dysplasia or cancer.
Identifiants
pubmed: 34757142
pii: S0016-5085(21)03710-0
doi: 10.1053/j.gastro.2021.10.038
pmc: PMC9341495
mid: NIHMS1824623
pii:
doi:
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468-481Subventions
Organisme : Doris Duke Charitable Foundation
ID : 2018089
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK109209
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA163060
Pays : United States
Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Clin Gastroenterol Hepatol. 2016 Jul;14(7):963-5
pubmed: 27001267
Semin Radiat Oncol. 2007 Jan;17(1):2-9
pubmed: 17185192
Hum Pathol. 2001 Apr;32(4):379-88
pubmed: 11331954
J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7
pubmed: 18695138
Histopathology. 2016 Sep;69(3):431-40
pubmed: 26918780
Gastroenterology. 2005 Dec;129(6):1825-31
pubmed: 16344051
Clin Gastroenterol Hepatol. 2009 Jul;7(7):736-42; quiz 710
pubmed: 19268726
Mod Pathol. 2015 Jun;28(6):758-65
pubmed: 25676554
Cancer Prev Res (Phila). 2015 Sep;8(9):845-56
pubmed: 26130253
Histopathology. 2017 Jul;71(1):27-33
pubmed: 28226185
Adv Ther. 2016 Apr;33(4):684-97
pubmed: 26942725
Gut. 2012 Jul;61(7):970-6
pubmed: 21997553
Gastroenterol Rep (Oxf). 2016 Nov;4(4):304-309
pubmed: 26486567
Histopathology. 2010 Jun;56(7):900-7
pubmed: 20636793
Gastroenterology. 2018 Jul;155(1):156-167
pubmed: 29608884
Cancer Res. 2009 May 15;69(10):4112-5
pubmed: 19435894
Int J Cancer. 2019 Nov 15;145(10):2754-2766
pubmed: 31001805
Hum Pathol. 1988 Feb;19(2):166-78
pubmed: 3343032
Gut. 2013 Dec;62(12):1676-83
pubmed: 23256952
Am J Surg Pathol. 2017 May;41(5):e8-e21
pubmed: 28248814
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Genes Chromosomes Cancer. 2015 Feb;54(2):82-90
pubmed: 25284618
Am J Gastroenterol. 2015 Jun;110(6):828-34
pubmed: 26010308
Gastroenterology. 2017 Apr;152(5):993-1001.e1
pubmed: 28012849
Mod Pathol. 2000 Jun;13(6):614-20
pubmed: 10874664
Am J Gastroenterol. 2010 Jul;105(7):1523-30
pubmed: 20461069
Nat Genet. 2015 Sep;47(9):1047-55
pubmed: 26192918
Nat Med. 2020 Nov;26(11):1726-1732
pubmed: 32895572